Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
SIRT6 siRNA engineered exosomes
- Development stage
- Preclinical
- Lead developer
- Shanghai Jiao Tong University
- Modality
- Chemically Modified siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Conjugated siRNA → Small Interfering RNA (siRNA) → Small RNA Therapeutics → RNA Therapeutics → Nucleic Acid Therapeutics, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
SIRT6 siRNA engineered exosomes is a preclinical, exosome-based gene-silencing therapeutic designed for the treatment of metastatic castration-resistant prostate cancer (mCRPC). The therapeutic consists of HEK293T cell-derived exosomes surface-modified with a cholesterol-conjugated E3 aptamer, which specifically targets prostate cancer cells. These engineered exosomes deliver a small interfering RNA (siRNA) payload that silences Sirtuin 6 (SIRT6), a deacetylase enzyme often overexpressed in advanced prostate cancer. By inhibiting SIRT6, the drug suppresses tumor proliferation and metastasis through the inhibition of the Notch signaling pathway and the reversal of epithelial-mesenchymal transition (EMT). This research-stage compound was developed by researchers at Shanghai Jiao Tong University and has demonstrated efficacy in xenograft mouse models.
- Other names
- aptamer-modified exosomes carrying SIRT6 siRNAE3 aptamer-modified exosomes carrying SIRT6 siRNAE-3 aptamer-modified exosomes carrying SIRT6 siRNAE 3 aptamer-modified exosomes carrying SIRT6 siRNA
02
Targets
SIRT6 (Sirtuin 6)
Beyond the preview
Go deeper on SIRT6 siRNA engineered exosomes.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on SIRT6 siRNA engineered exosomes.